Practical Recommendations for the Use of ACE Inhibitors, Beta-Blockers, Aldosterone Antagonists and Angiotensin Receptor Blockers in Heart Failure: Putting Guidelines into Practice
Практические рекомендации по применению ингибиторов АПФ, β-блокаторов, антагонистов альдостерона и блокаторов рецепторов ангиотензина при сердечной недостаточности: внедрение рекомендаций в практику
2005-08-01
SCID: 54.1/cqzwqdvh
Discuss with AI
ACE inhibitorsaldosterone antagonistsangiotensin receptor blockersbeta-blockersheart failure
Figures from the paper
Abstract (AI)
Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well-being and prolong life. This may be due to unfamiliarity with the evidence-base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events. ACE inhibitors have long been the cornerstone of therapy for systolic HF irrespective of aetiology. Recent trials have now shown that treatment with beta-blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome. In order to accelerate the safe uptake of these treatments and to ensure that all eligible patients receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of HF. The objective of these recommendations is to provide practical guidance for non-specialists, in order to increase the use of evidenced based therapy for HF. These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines.
Key Findings
1
ACE inhibitors remain the cornerstone of treatment for systolic heart failure regardless of etiology.
2
Clinical practice surveys reveal delays in adopting evidence-based pharmacological treatments for heart failure, depriving patients of therapies that improve well-being and prolong survival.
3
Clinical trials demonstrate that beta-blockers, aldosterone antagonists, and angiotensin receptor blockers substantially improve outcomes in heart failure.
4
The paper provides concise, practical recommendations to help non-specialists safely initiate appropriate heart-failure medications and increase evidence-based treatment uptake.
5
These recommendations are intended to supplement, not replace, existing heart-failure clinical guidelines.
Research Object
Pharmacological treatments for systolic heart failure, specifically ACE inhibitors, beta-blockers, aldosterone antagonists, and angiotensin receptor blockers
Research Subject
Practical, evidence-based guidance for the safe and appropriate use of these therapies to improve outcomes and accelerate their uptake in eligible heart-failure patients
Publication Details
Publication Date
2005-08-01
Journal
Publisher
ISSN
Cited by
130
Access Type
Author Information
Download PDF
Subscribe to digest